GRI Bio (GRI) vs Purple Biotech (PPBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
GRI Bio is the larger company by market cap ($2.4 million vs $1.9 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | PPBT |
|---|---|---|
| Share price | $1.12 | $1.53 |
| Market cap | $2.45M | $1.86M |
| 1-day change | 0.00% | -4.09% |
| P/E ratio (TTM) | 0.05 | — |
| EPS (TTM) | $20.57 | $-47.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-11.96M | $-26.39M |
| 52-week high | $64.12 | $8.90 |
| 52-week low | $1.09 | $0.91 |
| Distance from 52-week high | -98.25% | -82.87% |
| Analyst consensus | none | none |
| Avg. price target upside | +1551.79% | +1014.75% |
| Average volume | 218.31K | 1.26M |
| Shares outstanding | 2.19M | 1.22M |
| Employees | 3 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Purple Biotech
PPBT stock →Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and CAPTN-3 - IM1240 and IM1305, multi-valent antibody designed to activate anti-tumoral immune response against TAA positive tumors, which is in preclinical stage.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
GRI vs PPBT FAQ
Which is bigger, GRI Bio or Purple Biotech?
GRI Bio (GRI) is larger, with a market capitalization of $2.45M compared with $1.86M for Purple Biotech (PPBT).
Are GRI Bio and Purple Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.